Nephrology News

In patients with obesity and heart disease, semaglutide 2.4 mg reduced risk for major adverse cardiovascular events regardless of baseline kidney function, according to new data from the SELECT trial.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.

Discontinuation of renin-angiotensin system inhibitor therapy before major noncardiac surgery did not appear to affect postoperative outcomes vs. treatment continuation, a speaker reported.

Neighborhoods with higher socioeconomic disadvantage, particularly predominantly Black areas, had higher rates of hypertension and lower rates of BP treatment vs. less disadvantaged neighborhoods, researchers reported.

Medicine was an interesting thought as I was growing up with no medical people in my family.

Dietary acid reduction from fruits and vegetables or sodium bicarbonate improved kidney health in patients with hypertension and macroalbuminuria, findings from a randomized controlled trial showed.

In an analysis of more than 3 million U.S. adults, most patients with a class 1a recommendation for SGLT2 inhibitors were not prescribed them, researchers reported in the Journal of the American College of Cardiology.

Bayer announced positive top-line results for the FINEARTS-HF trial of finerenone, in which the drug reduced risk for cardiovascular death and heart failure events in patients with HF with preserved or mildly reduced ejection fraction.

Drugs used to treat diabetes and obesity, such as GLP-1 receptor agonists, are becoming an important treatment pathway in rheumatology, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.